[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100490715":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":12,"centralContacts":16,"locations":10,"responsibleParty":22,"collaborators":10,"id":24,"slug":25,"hasResults":26,"nctId":27,"briefTitle":28,"officialTitle":29,"acronym":10,"eligibilityCriteria":30,"healthyVolunteers":26,"sex":31,"minAge":32,"maxAge":10,"enrollmentInfo":33,"targetDuration":10,"studyType":36,"phases":10,"briefSummary":37,"conditions":38,"keywords":40,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":10},{"fullName":5,"class":6},"Takeda","INDUSTRY",[8],{"label":9,"type":10,"description":11,"interventionNames":10},"VPRIV® Home Infusion",null,"Participants diagnosed with Gaucher disease will receive VPRIV® home infusion, administered by their caregivers and home infusion nurses will participate in the survey and complete the non-nominative web-based questionnaires on Day 1.",[13],{"name":14,"affiliation":5,"role":15},"Study Director","STUDY_DIRECTOR",[17],{"name":18,"role":19,"phone":20,"phoneExt":10,"email":21},"Takeda Contact","CONTACT","+1-877-825-3327","medinfoUS@takeda.com",{"type":23,"investigatorFullName":10,"investigatorTitle":10,"investigatorAffiliation":10,"oldNameTitle":10,"oldOrganization":10},"SPONSOR","100490715","a-survey-to-assess-participants-caregivers-and-nurses-use-and-understanding-of-educational-material-on-velaglucerase-alfa-vpriv-home-infusion-100490715",false,"NCT05669729","A Survey to Assess Participants', Caregivers', and Nurses' Use and Understanding of Educational Material on Velaglucerase Alfa (VPRIV) Home Infusion","A Survey Among Patients, Caregivers and Home Infusion Nurses Based in the European Union to Assess Their Awareness and Understanding of Educational Materials Supporting VPRIV® Infusion at Home","Inclusion criteria:\n\n1. Gaucher disease participants who receive VPRIV® for home infusion and their caregivers.\n2. Home infusion nurses administering VPRIV® to participants with Gaucher disease at home.\n\nExclusion criteria:\n\nPotential respondents will be excluded if they have conflicts of interest with the survey (e.g., if they are employed by regulatory bodies, or pharmaceutical industry).","ALL","2 Years",{"count":34,"type":35},60,"ESTIMATED","OBSERVATIONAL","The main purpose of this survey is to determine participants', caregivers', and nurses' understanding and use of educational materials (EM) on VPRIV home treatment. EM includes an infusion diary and guide and an emergency plan related to VPRIV infusion given at home for Gaucher disease. The survey is conducted in European countries.\n\nData will be collected directly from participants, caregivers, and nurses in form of a questionnaire, electronic or paper.",[39],"Gaucher Disease",[41],"Drug Therapy","NOT_YET_RECRUITING","2026-03-30",{"date":45,"type":46},"2026-04-03","ACTUAL",{"date":48,"type":35},"2026-09-30",{"date":50,"type":35},"2027-09-30",{"name":5,"class":6}]